2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-125641
    AL-34662 210580-75-9 99.20%
    AL-34662 is a selective 5-HT2A receptoragonist (IC50: 0.77 nM and 1.5 nM for rat and human 5-HT2 receptor). AL-34662 is also a weak α-1D adrenergic agonist activity (EC50:0.4 μM). AL-34662 is an ocular hypotensive agent.
    AL-34662
  • HY-130309
    (±)8(9)-EpETE 851378-93-3 99.9%
    Eicosapentaenoic acid (EPA) is converted to epoxyeicosatetraenoic acids (EpETEs) by several cytochrome P450 isoforms. The major product of this epoxygenase pathway, (±)17(18)-EpETE, relaxes vascular and airway smooth muscle by activating large conductance Ca2+-activated K+ (BKCa) channels by directly interacting with BKα channel subunits. (±)8(9)-EpETE is an epoxygenase pathway product produced from EPA by CYP450 both in vitro and in vivo.
    (±)8(9)-EpETE
  • HY-130579
    Vinyl-L-NIO hydrochloride 728944-69-2
    Vinyl-L-NIO (L-VNIO) hydrochloride is a neuronal nitric oxide synthase (NOS) inhibitor with a rat Ki of 0.10 μM. Vinyl-L-NIO hydrochloride inhibits NADPH oxidase activity, attenuates renal fibrosis, inflammation, oxidative stress indices, and albuminuria. Vinyl-L-NIO hydrochloride can be used for the research of parkinson's disease, migraine headache, and hypertension.
    Vinyl-L-NIO hydrochloride
  • HY-13295R
    Vinpocetine (Standard) 42971-09-5 99.75%
    Vinpocetine (Standard) is the analytical standard of Vinpocetine. This product is intended for research and analytical applications. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
    Vinpocetine (Standard)
  • HY-134685
    Edoxaban impurity 6 480452-37-7 ≥98.0%
    Edoxaban impurity 6 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention.
    Edoxaban impurity 6
  • HY-137584
    1a,1b-Dihomo prostaglandin E1 23452-98-4 98.0%
    1a,1b-Dihomo prostaglandin E1 (1a,1b-Dihomo PGE1) is an E1-type prostaglandin. 1a,1b-Dihomo prostaglandin E1 can be used for research on platelet aggregation.
    1a,1b-Dihomo prostaglandin E1
  • HY-14268R
    Febuxostat (Standard) 144060-53-7 99.70%
    Febuxostat (Standard) is the analytical standard of Febuxostat. This product is intended for research and analytical applications. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout.
    Febuxostat (Standard)
  • HY-14299R
    Indacaterol (Standard) 312753-06-3 99.98%
    Indacaterol (Standard) is the analytical standard of Indacaterol. This product is intended for research and analytical applications. Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research.
    Indacaterol (Standard)
  • HY-153595
    DAPK-IN-2 304000-05-3 98.02%
    DAPK-IN-2 is a DAPK inhibitor. DAPK-IN-2 can be used for the research of cerebral infarction and ischemic diseases.
    DAPK-IN-2
  • HY-15515R
    SEA0400 (Standard) 223104-29-8 98.11%
    SEA0400 (Standard) is the analytical standard of SEA0400. This product is intended for research and analytical applications. SEA0400 is a novel and selective inhibitor of the Na+-Ca2+ exchanger (NCX), inhibiting Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia with IC50s of from 5 to 33 nM.
    SEA0400 (Standard)
  • HY-161940
    PCSK9-IN-30 98%
    PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC50 = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases.
    PCSK9-IN-30
  • HY-165084
    L-a-Phosphatidylserine sodium 383908-63-2 99.0%
    L-α-Phosphatidylserine sodium (Soy PS sodium) is a negatively charged phospholipid that acts as an allosteric activator to activate latent plasminogen activator inhibitor-1 (PAI-1). L-α-Phosphatidylserine does not directly alter the catalytic activity of t-PA, but regulates fibrinolytic activity solely by inducing conformational remodeling of PAI-1. L-α-Phosphatidylserine sodium is an antigen targeting phosphatidylserine (PS) and can induce the production of polyclonal antibodies. L-α-Phosphatidylserine is mainly used in studies related to immunology, fibrinolytic system and coagulation homeostasis.
    L-a-Phosphatidylserine sodium
  • HY-176971
    PPARα agonist 6 959699-23-1 99.79%
    PPARα agonist 6 (Compound 15) is a PPARα agonist. PPARα agonist 6 can be used in the research of dyslipidemia.
    PPARα agonist 6
  • HY-183372
    HIF-IN-2 1040535-05-4
    HIF-IN-2 is a HIF/HIF prolyl hydroxylase inhibitor. HIF-IN-2 suppresses HIF prolyl hydroxylase activity. HIF-IN-2 can be used for the research of anemia.
    HIF-IN-2
  • HY-185104
    Ginsenoside C-K hexapropionate ester 2861254-89-7 98.88%
    Ginsenoside C-K hexapropionate ester (Structure 2) is a selective agonist of LXRα, with no significant activation effect on LXRβ. Ginsenoside C-K hexapropionate ester upregulates the expression of downstream genes such as ABCA1 by activating LXRα, promoting reverse cholesterol transport, and reducing lipid deposition in macrophage-derived foam cells. It can be used in the research of atherosclerosis. Ginsenoside C-K hexapropionate ester is a derivative synthesized from ginsenoside Compound K, an active metabolite of Panax notoginseng saponins, by modification with propionic anhydride.
    Ginsenoside C-K hexapropionate ester
  • HY-401475
    Protein kinase inhibitor 9 262433-52-3
    Protein kinase inhibitor 9 (Compound example 175) is an inhibitor of serine/threonine and tyrosine kinase activity. Protein kinase inhibitor 9 can be used for the research of cancer, hyper proliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections and imflammatory disorders.
    Protein kinase inhibitor 9
  • HY-A0023R
    Alogliptin Benzoate (Standard) 850649-62-6 99.31%
    Alogliptin (Benzoate) (Standard) is the analytical standard of Alogliptin (Benzoate). This product is intended for research and analytical applications. Alogliptin Benzoate (SYR-322) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin Benzoate can be used for the research of type 2 diabetes.
    Alogliptin Benzoate (Standard)
  • HY-B0285R
    Amiloride (Standard) 2609-46-3 99.82%
    Amiloride (Standard) is the analytical standard of Amiloride. This product is intended for research and analytical applications. Amiloride (MK-870) is an inhibitor of both epithelial sodium channel (ENaC) and urokinase-type plasminogen activator receptor (uTPA). Amiloride is a blocker of polycystin-2 (PC2; TRPP2) channel.
    Amiloride (Standard)
  • HY-B0424R
    Nitrendipine (Standard) 39562-70-4 99.41%
    Nitrendipine (Standard) is the analytical standard of Nitrendipine (HY-B0424). This product is intended for research and analytical applications. Nitrendipine (BAY-E-5009) is an orally active analog of Nifedipine (HY-B0284) and dihydropyridine calcium channel blocker. Nitrendipine induces Apoptosis. Nitrendipine has antihypertensive effects. Nitrendipine blocks alcohol and Morphine withdrawal symptoms. Nitrendipine reduces right ventricular hypertrophy and pulmonary vascular changes induced by intermittent hypoxia. Nitrendipine has anticancer effects on neuroblastoma.
    Nitrendipine (Standard)
  • HY-B0471R
    Phenylephrine hydrochloride (Standard) 61-76-7 99.68%
    Phenylephrine (hydrochloride) (Standard) is the analytical standard of Phenylephrine (hydrochloride). This product is intended for research and analytical applications. (R)-(-)-Phenylephrine hydrochloride is a selective α1-adrenoceptor agonist with pKis of 5.86, 4.87 and 4.70 for α1D, α1B and α1A receptors respectively.
    Phenylephrine hydrochloride (Standard)
Cat. No. Product Name / Synonyms Application Reactivity